Ch 39Lower Respiratory Disorders: Comprehensive Study Notes

Lower Respiratory System Fundamentals

  • Lung Compliance

    • Refers to lung volume based on the pressure within the alveoli.

    • Factors influencing compliance:

      • Connective tissue.

      • Surface tension in the alveoli.

  • Control of Respiration

    • Influenced by the concentrations of oxygen (O<em>2O<em>2), carbon dioxide (CO</em>2CO</em>2), and hydrogen (H+H^+) ions in the blood.

  • Bronchial Smooth Muscle

    • Plays a significant role in airway diameter and resistance.

Lower Respiratory Disorders

  • Asthma

    • An inflammatory disorder affecting the airway walls.

    • Characterized by airway obstruction.

    • Triggers:

      • Stress.

      • Allergens.

      • Pollutants.

    • Signs/Symptoms:

      • Bronchospasm.

      • Dyspnea (shortness of breath).

      • Excessive mucus secretions.

      • Wheezing.

      • Coughing.

      • Tightness in the chest.

  • Bronchial Asthma: Pathophysiological Changes

    • Allergens attach to mast cells and basophils, initiating an antigen-antibody reaction on the mast cells.

    • Mast cells are stimulated to release chemical mediators (e.g., histamine, leukotrienes).

    • An inflammatory process ensues.

    • This leads to increased resistance to airflow due to airway obstruction.

    • Signs/Symptoms (reiterated):

      • Bronchospasm.

      • Wheezing.

      • Dyspnea.

      • Mucus secretions.

  • Chronic Bronchitis

    • Pathophysiological Changes:

      • Bronchial inflammation.

      • Excessive mucus secretions, leading to airway obstruction.

    • Causes:

      • Smoking.

      • Chronic lung infections.

    • Signs/Symptoms:

      • Productive cough.

      • Hypoxemia (low blood oxygen).

      • Rhonchi (coarse rattling sounds in the lungs).

      • Hypercapnia (high blood carbon dioxide).

      • Respiratory acidosis.

  • Bronchiectasis

    • Pathophysiological Changes:

      • Abnormal and irreversible dilation of the bronchi and bronchioles.

      • Bronchioles become obstructed due to the breakdown of the epithelium of the bronchial mucosa.

      • Tissue fibrosis may eventually occur.

    • Causes:

      • Frequent infections.

      • Persistent inflammation.

  • Emphysema

    • A progressive lung disease.

    • Pathophysiological Changes:

      • Proteolytic enzymes are released in the lung by bacteria or phagocytic cells.

      • Terminal bronchioles become plugged with mucus.

      • This leads to a loss in the fiber and elastin network within the alveoli.

      • Alveolar walls are destroyed.

      • Air becomes trapped in enlarged, overexpanded alveoli, resulting in inadequate gas exchange.

    • Causes:

      • Cigarette smoking.

      • Atmospheric contaminants.

      • Lack of the alpha1-antitrypsin protein.

  • Chronic Obstructive Pulmonary Disease (COPD)

    • Pathophysiological Changes:

      • Characterized by airway obstruction with increased airway resistance to airflow to lung tissues.

    • Major Causes:

      • Chronic bronchitis.

      • Bronchiectasis.

      • Emphysema.

      • Asthma (often considered a component or comorbidity that contributes to COPD features).

  • Restrictive Lung Disease

    • Pathophysiological Changes:

      • Involves a decrease in total lung capacity.

      • This is due to fluid accumulation and/or loss of elasticity of lung tissues.

    • Etiology (Causes):

      • Pulmonary edema.

      • Pulmonary fibrosis.

      • Pneumonitis.

      • Lung tumors.

      • Thoracic deformities (e.g., scoliosis).

      • Thoracic muscular disorders (e.g., myasthenia gravis).

Pharmacological Management of Lower Respiratory Disorders

  • Bronchodilators: Sympathomimetics

    • Epinephrine

      • Action: Increases cyclic adenosine monophosphate (cAMP) in lung tissue, leading to bronchodilation. It also restores circulation and increases airway patency.

      • Use: Acute bronchospasm, asthma, anaphylaxis, angioedema, nasal congestion, status asthmaticus.

      • Side Effects: Dizziness, tremors, hypertension, angina, palpitations, tachycardia, dysrhythmias, restlessness.

  • Bronchodilators: Selective Beta-Adrenergics

    • Albuterol

      • Action: Directly causes bronchodilation.

      • Properties: Rapid onset of action, longer duration of action compared to non-selective beta-agonists, generally few side effects.

      • Use: Asthma, acute bronchospasm, bronchospasm prophylaxis.

      • Common Side Effects: Headache, rhinitis, excitability, tremors, paradoxical bronchospasm, palpitations, tachycardia.

    • Metaproterenol

      • Administration: Inhalation is the preferred route for long-term asthma treatment.

      • Use: Acute bronchospasm, asthma, COPD.

      • Common Side Effects: Headache, dizziness, tremor, nausea, palpitations, tachycardia, angina.

  • Anticholinergics

    • Tiotropium

      • Use: Maintenance treatment of bronchospasms associated with COPD.

      • Administration: Administered by inhalation only using the HandiHaler device (a dry-powder capsule inhaler).

      • Common Side Effects: Dry mouth, constipation, GI distress, depression, insomnia, headache, pharyngitis, sinusitis, infection, arthralgia, peripheral edema.

  • Methylxanthine Derivatives

    • Theophylline

      • Action: Relaxes smooth muscle of the bronchi and bronchioles by increasing cAMP, thereby promoting bronchodilation.

      • Use: Asthma.

      • Therapeutic Range: 5−155-15 mcg/mL. Toxicity is generally observed when levels are greater than 2020 mcg/mL.

      • Side Effects/Adverse Effects: Dizziness, headache, irritability, restlessness, hypokalemia, GI distress, seizure, insomnia, tachycardia, palpitations, hypotension, dysrhythmias.

  • Leukotriene Receptor Antagonists (LTRAs)

    • Action: Reduce the inflammatory process and decrease bronchoconstriction.

    • Use: Asthma prophylaxis, prophylaxis of exercise-induced bronchospasm.

    • Important Note: Not recommended for acute asthmatic attacks.

    • Common Side Effects: Dizziness, headache, confusion, GI distress, depression, weakness, infection.

  • Glucocorticoids (Steroids)

    • Action: Primarily exert an antiinflammatory effect.

    • Administration: Can be given via MDI inhaler, orally as a tablet, or intravenously.

    • Side Effects: Dry mouth, throat irritation, hoarseness, cough, headache, euphoria, confusion, depression, hyperglycemia, GI distress, hypertension, insomnia, weakness, fluid retention, diaphoresis, osteoporosis, psychosis, superinfections (e.g., oral candidiasis), menstrual irregularities, electrolyte imbalance.

  • Cromolyn

    • Action: Inhibits histamine release, effectively preventing asthmatic attacks.

    • Use: Prophylaxis of bronchial asthma.

    • Common Side Effects: Cough, postnasal drip.

    • Adverse Effect: Rebound bronchospasm.

  • Drug Therapy for Asthma According to Severity

    • Chronic Asthma: Managed with a long-term medication program. A quick-relief program is also used for the acute phase. The specific long-term program can vary based on asthma symptoms and severity.

  • Drug Therapy for Asthma According to Age

    • Young Children: Cromolyn is used to treat the inflammatory effects of asthma. Oral glucocorticoids may be prescribed to control moderate to severe asthmatic states.

    • Older Adults: Requires careful consideration of drug selection and dosage due to potential adverse effects and comorbidities.

Clinical Judgment in Medication Administration

  • Bronchodilator Administration

    • Concept: Oxygenation.

    • Recognize Cues: Assess for wheezing, decreased breath sounds, cough, sputum production, and patient's hydration status.

    • Analyze Cues and Prioritize Hypothesis: Address dyspnea and decreased gas exchange.

    • Generate Solutions: Aim for the patient's wheezing to be eliminated or significantly diminished; expect lung fields to clear within 22 to 55 days.

    • Take Action:

      • Monitor vital signs regularly.

      • Ensure adequate hydration (oral or intravenous).

      • Observe for and document any side effects.

      • Administer medication at regular intervals around the clock to maintain a sustained therapeutic level.

      • Advise patients experiencing asthmatic attacks to wear an identification bracelet or MedicAlert tag.

    • Evaluate Outcomes: Regularly assess the effectiveness of the intervention against the generated solutions.

  • Leukotriene Receptor Antagonist Administration

    • Concept: Oxygenation.

    • Recognize Cues: Assess for wheezing, decreased breath sounds, cough, sputum production, and patient's hydration status.

    • Analyze Cues and Prioritize Hypothesis: Address dyspnea and airway obstruction.

    • Generate Solutions: Aim for the patient's lung fields to be clear within 22 to 55 days.

    • Take Action:

      • Monitor respirations for rate, depth, rhythm, and type.

      • Monitor lung sounds for rhonchi, wheezing, or rales.

      • Observe lips and fingernails for cyanosis.

      • Monitor liver function tests periodically, as some LTRAs can affect liver function.

      • Encourage the patient to stop smoking.

      • Advise patients who experience frequent or severe asthmatic attacks to wear an identification bracelet or MedicAlert tag.

    • Evaluate Outcomes: Continually assess patient response and adjust care as needed.

Practice Questions and Key Learnings

  • Metaproterenol Side Effects: Tremors are a common side effect of metaproterenol and other beta-adrenergic agonists.

  • Albuterol Action: Albuterol dilates the bronchioles, providing relief from bronchospasm. (The phrasing